Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill

Executive Summary

The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee

You may also be interested in...



FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden

Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies

FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden

Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies

PhRMA’s Compromise Offer On Drug Safety Would “Clarify” FDA’s Powers

The Pharmaceutical Research and Manufacturers of America is proposing reforms to FDA's safety powers that would allow quicker regulatory actions, but not fundamentally alter the agency's authority

Related Content

UsernamePublicRestriction

Register

PS048476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel